DOCSLIB.ORG

Gavi's Vaccine Investment Strategy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Gavi’s Vaccine Investment Strategy Deepali Patel THIRD WHO CONSULTATION ON GLOBAL ACTION PLAN FOR INFLUENZA VACCINES (GAP III) Geneva, Switzerland, 15-16 November 2016 www.gavi.org Vaccine Investment Strategy (VIS) Evidence-based approach to identifying new vaccine priorities for Gavi support Strategic investment Conducted every 5 years decision-making (rather than first-come- first-serve) Transparent methodology Consultations and Predictability of Gavi independent expert advice programmes for long- term planning by Analytical review of governments, industry evidence and modelling and donors 2 VIS is aligned with Gavi’s strategic cycle and replenishment 2011-2015 Strategic 2016-2020 Strategic 2021-2025 period period 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 RTS,S pilot funding decision VIS #1 VIS #2 VIS #3 MenA, YF mass campaigns, JE, HPV Cholera stockpile, Mid 2017 : vaccine ‘long list’ Rubella, Rabies/cholera studies, Oct 2017 : methodology Typhoid Malaria – deferred Jun 2018 : vaccine shortlist conjugate Dec 2018 : investment decisions 3 VIS process Develop Collect data Develop in-depth methodology and Apply decision investment decision framework for cases for framework with comparative shortlisted evaluation analysis vaccines criteria Phase I Narrow long list Phase II Recommend for Identify long list to higher priority Gavi Board of vaccines vaccines approval of selected vaccines Stakeholder consultations and independent expert review 4 Evaluation criteria (VIS #2 – 2013) Additional Health Implementation Cost and value impact impact feasibility for money considerations Impact on child Capacity and supplier Vaccine procurement Epidemic potential mortality base cost1 Impact on overall Global or regional GAVI market shaping In-country mortality public health priority potential operational cost Impact on overall Ease of supply chain Procurement cost per Herd immunity morbidity integration event averted2 Availability of Ease of alternative programmatic interventions integration Socio-economic Vaccine efficacy and inequity safety Gender inequity Disease of regional importance 5 1. Procurement cost includes vaccine, syringe, safety box, and freight 2. Scoring based on cost per future death averted How was maternal influenza vaccine assessed in VIS 2013? (I) Health Impact: Total future deaths averted per 100K vaccinated, 2015-2030 Value for Money: Cost per death averted, 2015-2030 (USD, ’000) How was maternal influenza vaccine assessed in VIS 2013? (II) Benefits Challenges • Potentially high impact across 3 key • Uncertainty about data for infant and groups: pregnant women, foetuses, foetal mortality infants • Requires change in manufacturer • Opportunity to strengthen maternal production (from once a year to year- immunisation platform and Gavi's round) and/or change in stock management for once-yearly release contribution to maternal and child health • Low country demand (and understanding of disease burden) vis-à-vis other vaccine • Low cost per death averted priorities Recommendations: • No funding window at this time • Monitor results of studies on fetal, neonatal and infant mortality • Evaluate implementation feasibility, logistics of seasonal vaccine supply, surveillance and strain matching, and optimal delivery strategies for pregnant women in the next VIS 7 A preliminary look at candidate investments in scope for consideration in VIS #3 (2018) Returning candidates: Incremental investments: New : • RTS,S • Meningococcal multivalent • RSV • Dengue (conjugate) • Group B • Maternal influenza • Cholera (routine and/or Streptococcus extended stockpile) • Rabies PEP • Norovirus? • DTP booster • Hepatitis E • ETEC? • Hepatitis B birth dose • Typhoid conjugate • PCV catch-up • Hexavalent (penta/IPV) • Ebola Data gathering to 2017 begin in 2017 8 Some key inputs needed for next VIS Relevance/demand • Expected demand from Gavi-eligible countries over 10-15 year timeframe? • Priority vs. other (outstanding) vaccine introductions, other public health priorities, and available alternative interventions? Implementation & coverage • Likely vaccination strategy in Gavi-eligible countries? Eg, target population, dosing, schedule, national/sub-national • What coverage could realistically be achieved in the target population? • Key barriers to reaching the target population? Impact • Efficacy, duration of protection, disease burden in Gavi countries? • Impact on inequity? Outbreak preparedness? Cost • Per dose or per target person cost range? Implementation costs? 9 THANK YOU www.gavi.org Gavi-supported vaccines * Refers to theRefers first Gavi-supportedto the first Gavi-supported introduction introduction of each vaccine. of each vaccine. *Contribution towards cholera vaccine stockpile for outbreak response 2014-2018 11 Maternal influenza vaccine – VIS 2013 ‘scorecard’ Phase I Category VIS Criteria Phase I Indicator Evaluation 170,000 U5 future deaths averted, 2015 – 2030 Impact on child mortality 46 U5 future deaths averted per 100,000 vaccinated pop 200,000 total future deaths averted, 2015 – 2030 Health Impact on overall mortality 56 total future deaths averted per 100,000 vaccinated pop impact 5.8 million total future cases averted, 2015 – 2030 Impact on overall morbidity 1600 total future cases averted per 100,000 vaccinated pop No long term sequelae Epidemic potential No disruptive epidemic potential Global or regional public health priority No global or regional resolution on elimination or eradication Additional Herd immunity Herd immunity threshold of ~80% impact Availability of alternative interventions No alternative to prevent; case management to alleviate symptoms consid- erations Socio-economic inequity No disproportionate impact on poor Gender inequity Pregnant women are at higher risk of death and severe disease Disease of regional importance Disease burden distributed across GAVI countries Capacity and supplier base Current capacity meets >100% of GAVI demand; 20+ manufacturers by 2020 GAVI market shaping potential GAVI demand <10% of global demand Imple- Ease of supply chain integration Packed volume between 3 and 12 cc / dose (5.8 cc / dose) mentation Fully aligns with neonatal tetanus vaccine schedule, possible need for behavior Ease of programmatic integration feasibility change due to off-label vaccine use in pregnant women ~70% vaccine efficacy in adults; 63% in <6 month olds through transfer of Vaccine efficacy and safety protection from mother to child; no evidence of causal link to adverse events Vaccine procurement cost1 $490 million procurement cost to GAVI and countries, 2015 - 2030 Cost and value for In-country operational cost Low: routine delivery within health system, single dose $2400 procurement cost per death averted, $84 procurement cost per case money Procurement cost per event averted2 averted 12 1. Procurement cost includes vaccine, syringe, safety box, and freight 2. Scoring based on cost per future death averted.
Recommended publications
  • Yellow Fever 2016

    Yellow Fever 2016

    Resident / Humanitarian Coordinator Report on the use of CERF funds RESIDENT / HUMANITARIAN COORDINATOR REPORT ON THE USE OF CERF FUNDS ANGOLA RAPID RESPONSE YELLOW FEVER 2016 RESIDENT/HUMANITARIAN COORDINATOR Pier Paolo Balladelli REPORTING PROCESS AND CONSULTATION SUMMARY a. Please indicate when the After Action Review (AAR) was conducted and who participated. Review agreed on 02/09/2016 and 07/09/2016. b. Please confirm that the Resident Coordinator and/or Humanitarian Coordinator (RC/HC) Report was discussed in the Humanitarian and/or UN Country Team and by cluster/sector coordinators as outlined in the guidelines. YES NO c. Was the final version of the RC/HC Report shared for review with in-country stakeholders as recommended in the guidelines (i.e. the CERF recipient agencies and their implementing partners, cluster/sector coordinators and members and relevant government counterparts)? YES NO Final version shared with UNICEF and UNDP, although this initiative was mainly implemented by WHO 2 I. HUMANITARIAN CONTEXT TABLE 1: EMERGENCY ALLOCATION OVERVIEW (US$) Total amount required for the humanitarian response: Source Amount CERF 3,000,000 Breakdown of total response COUNTRY-BASED POOL FUND (if applicable) 4,508,559 funding received by source OTHER (bilateral/multilateral) TOTAL 10,473,618 *The total amount does not match because this was considered an underfunded emergency. TABLE 2: CERF EMERGENCY FUNDING BY ALLOCATION AND PROJECT (US$) Allocation 1 – date of official submission: 06/04/2016- 05/10/2016 Agency Project code Cluster/Sector
  • Package Insert

    Package Insert

    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------------- CONTRAINDICATIONS ------------------------------------- These highlights do not include all the information needed to use ® • History of severe allergic reactions (e.g., anaphylaxis) to egg proteins, or any FLUVIRIN (Influenza Virus Vaccine) safely and effectively. See full ® ® component of FLUVIRIN , or life-threatening reactions to previous influenza prescribing information for FLUVIRIN . vaccinations. (4.1, 11) FLUVIRIN® (Influenza Virus Vaccine) Suspension for Intramuscular Injection ---------------------- WARNINGS AND PRECAUTIONS ------------------------------ 2017-2018 Formula • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior Initial US Approval: 1988 influenza vaccine, the decision to give FLUVIRIN® should be based on -------------------------- INDICATIONS AND USAGE ---------------------------------- careful consideration of the potential benefits and risks. (5.1) ® • FLUVIRIN is an inactivated influenza virus vaccine indicated for active • Immunocompromised persons may have a reduced immune response to immunization of persons 4 years of age and older against influenza disease FLUVIRIN®. (5.2) caused by influenza virus subtypes A and type B contained in the vaccine (1). • The tip caps of the FLUVIRIN® prefilled syringes may contain natural rubber • FLUVIRIN® is not indicated for children less than 4 years of age because latex which may cause allergic reactions in latex sensitive individuals. there is evidence of diminished immune response
  • Hanna Nohynek @Hnohynek

    Hanna Nohynek @Hnohynek

    Biosketch Hanna Nohynek @hnohynek Hanna Nohynek is Chief Physician and Deputy Head of the Infectious Diseases Control and Vaccines Unit of the Department of Health Security at the Finnish Institute for Health and Welfare. She serves as secretary of the Finnish NITAG (KRAR), and leads the subgroup on Strategic development of the influenza vaccination programme and the subgroup on the SARS-CoV-2 vaccination strategy. She practices clinical medicine at a travel health clinic in Aava, Helsinki. She was instrumental in designing the first THL (KTL) health advisory for refugees and asylum seekers in Finland, studying the narcolepsy signal post pandemic vaccination, designing the introduction of the HPV vaccine to the national immunization programme, and the introduction of the live attenuated influenza vaccine for children. Her present research interests are register-based vaccine impact studies, evidence based policy/decision making, vaccine safety, hesitancy, SARS-CoV-2, RSV, influenza and pneumococcus. She coordinates the work packages on field studies and communication for IMI DRIVE on brand specific influenza vaccine effectiveness (www.drive-eu.org). She has authored more than 130 original articles (including the first scientific report on the association between pandemic influenza vaccination and narcolepsy), and she teaches, giving over 30 invited lectures annually and guiding elective, graduate and PhD students (presently Raija Auvinen and Idil Hussein). She belongs to the external faculty of the University of Tampere MSc course on Global Health. She has served on expert committees evaluating HBV, PCV and rota virus vaccines in Finland, and as an advisor to the EU, IMI, IVI, WHO, GAVI, SIDA/SRC, and the Finnish MOFA.
  • UNEP Mercury Treaty Protects Access to Thiomersal-Containing Vaccines

    UNEP Mercury Treaty Protects Access to Thiomersal-Containing Vaccines

    UNEP mercury treaty protects access to thiomersal-containing vaccines United Nations Environment Program has developed a treaty on mercury in an effort to protect human health and the environment by limiting mercury releases. In the course of the negotiations, a proposal was made to restrict vaccines that contain the preservative thiomersal under a section of the treaty that prohibits trade of mercury-added products. The implications of restricting thiomersal, an ethyl mercury-containing preservative, would be significant. According to SAGE, “Thiomersal-containing vaccines [are] safe, essential, and irreplaceable components of immunization programs, especially in developing countries, and…removal of these products would disproportionately jeopardize the health and lives of the most disadvantaged children worldwide.” The treaty annex that describes prohibited products specifically excludes “vaccines containing thiomersal as preservatives” under a short list of products the authors intended to emphasize were to be protected. Protecting access to vaccines came as the result of a strong partnership between WHO, UNICEF, GAVI, and civil society advocates and experts around the world to educate country delegates, who predominantly came from ministries of environment. This was also a wonderful partnership with animal health experts, who similarly rely on thiomersal for veterinary vaccines. By facilitating communication between ministries of health and ministries of environment, strong statements are made by delegates about the essential role of thiomersal-containing vaccines in protecting human health. PATH will be collecting and disseminating additional information about how the community came together around this issue and lessons learned in the coming months. .
  • Cheat Sheet: COVID-19 Vaccine Pipeline

    Cheat Sheet: COVID-19 Vaccine Pipeline

    Cheat Sheet: COVID-19 vaccine pipeline Primary sponsor(s) Description Platform Funders Status Considerations Read more Pfizer / BioNTech Comirnaty mRNA Pfizer ($500M) Ph. I/II ongoing: 456/Germany Efficacy: Interim analysis shows that the candidate was safe and well-tolerated with New York Times mRNA that encodes for USG ($1.9M) Ph. II planned: 960/China an efficacy rate of 95%. SARS-CoV-2 spike protein. Warp Speed Finalist Ph. II/III ongoing: 44K US +5 Manufacturing/delivery: mRNA vaccines are relatively easy to scale and Authorization: EUA in EU, US, +9; WHO manufacture. Emergency Validation Platform history: No previous mRNA vaccines licensed for use. Approval: Bahrain, New Zealand, Saudi Arabia, Switzerland Moderna mRNA-1273 mRNA USG ($2.48B) Ph. I ongoing: 155/US Efficacy: Interim analysis shows that the candidate was safe and well-tolerated Moderna Synthetic messenger RNA CEPI/GAVI (Undisclosed) Ph. II/III ongoing: 3000 (12 to 17 years)/ US with an efficacy rate of 94.5%. Statement that encodes for SARS- Warp Speed Finalist Ph. III ongoing: 30,000/US Manufacturing/delivery: mRNA vaccines are relatively easy to scale and CoV-2 spike protein. COVAX Portfolio Authorization: EUA in Canada, EU, manufacture (potential for 1B doses by 2022); likely to require two doses, but a AVAC Israel, US third may be necessary. Webinar Approval: Switzerland Platform history: No previous mRNA vaccines licensed for use. U. of Oxford AZD1222 Viral USG ($1.2B) Ph. II ongoing: 300 vols (6-17 years)/ UK Efficacy: Ph. III interim analysis shows vaccine was safe and well-tolerated, efficacy Science AstraZeneca Chimpanzee Adeno vector vector CEPI/GAVI ($750M) Ph.
  • Global Challenges in Seasonal Influenza Vaccine Supply, Use, and Policy

    Global Challenges in Seasonal Influenza Vaccine Supply, Use, and Policy

    Intersect, Vol 12, No. 1 (2018) Global Challenges in Seasonal Influenza Vaccine Supply, Use, and Policy Kaitlin Schroeder Stanford University Abstract Seasonal influenza outbreaks occur on every continent, infecting millions and killing around 500,000 patients each year. The 2018 influenza season has been a vicious one—the H3N2 strain is a fast-mutating, aggressive form of the virus, and we have had difficulty immunizing against it. Decreasing the devastation of seasonal influenza starts with smart vaccine systems: a greater supply of doses distributed to the right people. In this review, we evaluate the global threat of seasonal influenza and explore the availability of vaccines as an essential prevention mechanism. We first identify key stakeholders in global influenza policy, vaccine supply, and regional public health governance. Next, we define the extent of the need for vaccines by examining surveillance systems and assessing the current disease burden of seasonal influenza. We examine current challenges in vaccine availability and allocation, and their respective impacts on health outcomes. Finally, we discuss policy implications of supply and allocation studies; we particularly note the promising outlook of communication programs, the advantages of optimized dose distribution, and the need to concentrate on infrastructure in low-income countries. Schroeder, Global Influenza Vaccine Challenges Introduction “Vaccines are miracles.” Professor Pedro Alonso of the Institute of Global Health, Barcelona explains that just a few dollars spent on immunization can protect an individual from severe disease and disability, making vaccines “one of the best investments in health” (Robert, n.d.). Among the recognized vaccine-preventable diseases (VPDs) is seasonal influenza, an acute viral infection that affects millions of people worldwide every year.
  • Yellow Fever Vaccine

    Yellow Fever Vaccine

    Yellow Fever Vaccine: Current Supply Outlook UNICEF Supply Division May 2016 0 Yellow Fever Vaccine - Current Supply Outlook May 2016 This update provides revised information on yellow fever vaccine supply availability and increased demand. Despite slight improvements in availability and the return of two manufacturers from temporary suspension, a constrained yellow fever vaccine market will persist through 2017, exacerbated by current emergency outbreak response requirements. 1. Summary Yellow fever vaccine (YFV) supply through UNICEF remains constrained due to limited production capacity. Despite the return of two manufacturers from temporary suspension, the high demand currently generated from the yellow fever (YF) outbreak in Angola, in addition to potential increased outbreak response requirements in other geographic regions, outweigh supply. The demand in response to the current YF outbreak in Angola could negatively impact the supply availability for some routine immunization programme activities. UNICEF anticipates a constrained global production capacity to persist through 2017. UNICEF has long-term arrangements (LTAs) with four YFV suppliers to cover emergency stockpile, routine immunization, and preventative campaign requirements. During 2015, UNICEF increased total aggregate awards to suppliers to reach approximately 98 million doses for 2016- 2017. However, whereas supply can meet emergency stockpile and routine requirements, it is insufficient to meet all preventive campaign demands, which increased the total demand through UNICEF to 109 million doses. The weighted average price (WAP) per dose for YFV increased 7% a year on average since 2001, from US$ 0.39 to reach US$ 1.04 in 2015. Given the continued supply constraints, UNICEF anticipates a YFV WAP per dose of US$1.10 in the near-term.
  • An Overview of COVID Vaccine Clinical Trial Results & Some Challenges

    An Overview of COVID Vaccine Clinical Trial Results & Some Challenges

    An overview of COVID vaccine clinical trial results & some challenges DCVMN Webinar December 8th, 2020 Access to COVID-19 tools ACCESSACCESS TO TOCOVID-19 COVID-19 TOOLS TOOLS (ACT) (ACT) ACCELERATOR ACCELERATOR (ACT) accelerator A GlobalA GlobalCollaboration Collaboration to Accelerate tothe AccelerateDevelopment, the Production Development, and Equitable Production Access to New and Equitable AccessCOVID-19 to New diagnostics, COVID-19 therapeutics diagnostics, and vaccines therapeutics and vaccines VACCINES DIAGNOSTICS THERAPEUTICS (COVAX) Development & Manufacturing Led by CEPI, with industry Procurement and delivery at scale Led by Gavi Policy and allocation Led by WHO Key players SOURCE: (ACT) ACCELERATOR Commitment and Call to Action 24th April 2020 ACT-A / COVAX governance COVAX COORDINATION MEETING CEPI Board Co-Chair: Jane Halton Co-Chair: Dr. Ngozi Gavi Board Workstream leads + DCVMN and IFPMA-selected Reps As needed – R&D&M Chair; COVAX IPG Chair Development & Manufacturing Procurement and delivery Policy and allocation (COVAX) at scale Led by (with industry) Led by Led by R&D&M Investment Committee COVAX Independent Product Group Technical Review Group Portfolio Group Vaccine Teams SWAT teams RAG 3 COVAX SWAT teams are being set up as a joint platform to accelerate COVID- 19 Vaccine development and manufacturing by addressing common challenges together Timely and targeted Multilateral Knowledge-based Resource-efficient Addresses specific cross- Establishes a dialogue Identifies and collates Coordinates between developer technical and global joint effort most relevant materials different organizations/ challenges as they are across different COVID-19 and insights across the initiatives to limit raised and/or identified vaccines organizations broader COVID-19 duplications and ensure on an ongoing basis (incl.
  • Recommended Adult Immunization Schedule

    Recommended Adult Immunization Schedule

    Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m.
  • Human Papillomavirus Vaccine

    Human Papillomavirus Vaccine

    Human Papillomavirus Vaccine: Supply and Demand Update UNICEF Supply Division October 2020 0 Human Papillomavirus Vaccine Supply and Demand Update - October 2020 This update provides information on human papillomavirus vaccine, including supply, demand, and pricing trends. It highlights continued supply constraints foreseen over 2020 and 2021, which also affects countries procuring through UNICEF. UNICEF requests self-financing middle-income countries to consolidate credible multi-year demand and to submit multi-year commitments through UNICEF. 1. Summary • UNICEF’s strategic plan for 2018-2021 seeks to ensure that at least 24 countries nationally introduce human papillomavirus (HPV) vaccine into their immunization programmes.1 As of to date, 20 countries supplied through UNICEF, of which 15 supported by Gavi, the Vaccine Alliance (Gavi) and five countries having transitioned from Gavi support and self-finance their procurement, have introduced HPV vaccines since 2013. Fourteen middle-income countries (MICs) are also procuring HPV vaccines through UNICEF. From 2013 to 2019, UNICEF’s total HPV vaccine procurement reached 30.9 million doses in support of girls. There is currently no gender-neutral programmes in countries supplied through UNICEF. Of the 30.9 million doses, UNICEF procured 28.3 million doses (91 per cent) for countries supported by Gavi, including those that transitioned from Gavi support and still access Gavi prices, and 2.6 million doses (9 per cent) on behalf of self-financing MICs. • In December 2016, Gavi revised its programme strategy to support full-scale national HPV vaccine introductions with multi-age cohort (MAC) vaccinations. This substantially increased HPV vaccine demand through UNICEF from 2017.
  • 'Astrazeneca' Covid-19 Vaccine

    'Astrazeneca' Covid-19 Vaccine

    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
  • UNICEF Deep-Dive 2020, Vaccine Industry Consultation UNICEF’S Tentative Vaccine Tender Calendar for the Upcoming Period INFLUENZA Deep-Dive Agenda

    UNICEF Deep-Dive 2020, Vaccine Industry Consultation UNICEF’S Tentative Vaccine Tender Calendar for the Upcoming Period INFLUENZA Deep-Dive Agenda

    UNICEF Deep-dive 2020, Vaccine Industry Consultation UNICEF’s Tentative Vaccine Tender Calendar for the upcoming period INFLUENZA Deep-dive Agenda • Background and challenges • Feedback from the industry • Gavi learning agenda for seasonal influenza​ • Tender timelines • Key takeaways 4 Background & Challenges • Immunization programmes, vaccines, and auxiliary supplies for seasonal influenza are primarily funded through a country’s own health budget. • Due to limited funding, seasonal influenza programmes are often not implemented in LICs and MICs. • Historically, UNICEF has procured limited quantities of influenza vaccine on behalf of countries. • UNICEF often receives requests for supply of seasonal influenza vaccine late and after suppliers have determined the production volume for the global market. • Due to COVID-19, the demand for seasonal influenza vaccines through UNICEF has increased during 2020, and realized late which let to constrained availability for countries procuring through UNICEF. UNICEF plans to tender earlier to counter this risk. Feedback from the industry What should UNICEF do differently to incentivize your participation in the future tenders for seasonal influenza vaccines? Feedback from the industry Measures taken by UNICEF • Tender one year in advance to block the • Advance tender timelines​ doses for UNICEF. • Stakeholders reminded of: • Multi-year tender and LTA​ o the short window for production planning and supply​ • UNICEF take risks and commit to pay for o importance of timely and accurate the doses even they are not materialised forecasting​ into orders. • Published a Supply Note on Seasonal Influenza Vaccines in English & French. • Working with countries to improve longer- term forecast accuracy. 6 Gavi learning agenda for seasonal influenza • Background: only 8% of Gavi eligible • Duration of the project: 2021 – 2022 countries have seasonal influenza immunization programmes, and most • Targeted countries: Cote d’Ivoire, Kenya & countries in the African region do not have Uganda national influenza immunization policies.